Zacks Research Issues Pessimistic Estimate for ALNY Earnings

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Equities research analysts at Zacks Research dropped their Q2 2025 earnings per share (EPS) estimates for Alnylam Pharmaceuticals in a research note issued on Monday, January 27th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings of ($0.97) per share for the quarter, down from their prior estimate of ($0.96). The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($2.24) per share. Zacks Research also issued estimates for Alnylam Pharmaceuticals’ Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($3.11) EPS, Q3 2026 earnings at $0.68 EPS, Q4 2026 earnings at $0.67 EPS and FY2026 earnings at $1.86 EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. The firm’s revenue for the quarter was down 33.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.15 earnings per share.

A number of other analysts have also recently weighed in on ALNY. Scotiabank increased their price target on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a research note on Friday, November 1st. Barclays increased their target price on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. Bank of America boosted their price target on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Piper Sandler reaffirmed an “overweight” rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Finally, Canaccord Genuity Group boosted their target price on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $298.61.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $277.16 on Thursday. The company’s 50 day simple moving average is $250.02 and its 200-day simple moving average is $260.77. The firm has a market cap of $35.75 billion, a PE ratio of -105.79 and a beta of 0.34. Alnylam Pharmaceuticals has a 12-month low of $141.98 and a 12-month high of $304.39. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of large investors have recently bought and sold shares of ALNY. Jennison Associates LLC purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter worth $61,160,000. Strategic Financial Concepts LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $41,529,000. Eventide Asset Management LLC grew its stake in shares of Alnylam Pharmaceuticals by 157.9% in the third quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company’s stock valued at $61,698,000 after buying an additional 137,333 shares in the last quarter. Los Angeles Capital Management LLC raised its holdings in shares of Alnylam Pharmaceuticals by 11,433.4% during the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock valued at $37,684,000 after buying an additional 135,829 shares during the period. Finally, Telemark Asset Management LLC acquired a new position in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $27,503,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 52,592 shares of the company’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the transaction, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,416,865. This represents a 81.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Phillip A. Sharp sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. Insiders sold 73,964 shares of company stock valued at $20,622,925 in the last 90 days. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.